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Abstract—Chemical conjugates between sodium cellulose sulfate (CS), displaying contraceptive and HIV-entry inhibiting properties, 
and nucleoside reverse transcriptase inhibitors (NRTIs) (3′-azido-2′,3′-dideoxythymidine (AZT), 3′-fluoro-2′,3′-dideoxythymidine (FLT), 
or 2',3'-dideoxy-3'-thiacytidine (3TC)) were designed to simultaneously provide contraceptive and anti-HIV activity. Two linkers, acetate 
and succinate, were used to conjugate the nucleoside analogs with CS. The conjugates containing cellulose sulfate-acetate (CSA) (e.g., 
AZT-CSA and FLT-CSA) were found to be more potent than CS and other conjugates (e.g., AZT-succinate-CS, and FLT-succinate-CS). 
The presence of both sulfate and the acetate groups on cellulose were critical for generating maximum anti-HIV activity. In addition to 
showing equal potency against wild-type and multidrug resistant HIV-1, the AZT-CSA conjugate displayed significant contraceptive 
activity in an animal model, providing the initial proof-of-concept for the design and synthesis of dual-activity compounds based on these 
combinations. 
Unplanned pregnancies and sexually transmitted 
infections, including HIV/AIDS, affect millions of 
women each year providing the rationale for the 
development of novel multi-purpose prevention 
technologies.1 Sulfonate and sulfate polyanionic 
compounds inhibit HIV entry into host cells2−5 and also 
display sperm-function inhibiting properties.6,7 
Polyanionic sulfates are polymers, such as dextran, 
cellulose, styrene, with sulfate groups in their 
structure.3,5,8,9 In our attempt to develop novel dual-
activity compounds, we conjugated polyanionic 
cellulose derivatives with known HIV nucleoside 
reverse transcriptase inhibitors (NRTIs). 
The viral envelope protein gp120 is known to have 
positively charged residues in its V3 loop. HIV entry in 
host cell depends on the virus interactions with the 
negatively charged surfaces of the coreceptors CXCR4 
and CCR5.10 Polyanionic sulfates exhibit their 
inhibitory activity by blocking these interactions.11−14 
Different strains of HIV are known to have different 
gp120 V3 loops. X4-strains of HIV, for instance, 
possess a higher positive charge density on their V3 
loop than R5 strains.8,14,15 This property of X4 makes 
them more susceptible to polyanionic inhibitors. Certain 
polyanionic derivatives like dextran sulfate and heparin 
show weak inhibitory activity against R5 HIV strains. 
11,16
 
Sodium cellulose sulfate (Ushercell, CS, 1) is a 
polyanionic non-cytotoxic microbicide and its 6% gel 
has been studied as a vaginal contraceptive and a broad-
spectrum antimicrobial agent, both preclinical and 
clinically.7,17,18 Similar to other polyanionic derivatives, 
CS (1) interacts with the positively charged viral 
envelope proteins, and prevents virus cell entry. Various 
preclinical studies showed that CS possesses significant 
anti-HIV activity against both strains of virus, but it is 
more active against X4 tropic than R5 tropic HIV.16,19 
In addition to antimicrobial activity, CS also 
showed contraceptive activity because of its ability to 
inhibit sperm enzymes (e.g., hyaluronidase; IC50 = 1.7 
mg/ml), which are important for sperm-egg 
interaction.17 CS also inhibits sperm penetration of 
cervical mucus.17 In a noncomparative contraceptive 
effectiveness trial of 6% CS gel involving 200 couples 
who used the product for 6 month as their only method 
of contraception, CS showed similar effectiveness rates 
to those of commercial spermicides.7 
CS showed promising results in the preclinical 
studies and phases I and II clinical trials sponsored by 
CONRAD. In preclinical studies, CS prevented 
conception in rabbits when applied vaginally before 
insemination, and was also found to inhibit HIV, 
Neisseria gonorrhoeae, and Chlamydia 
trachomatis.6,17,20 Results from phase I clinical trials 
showed that CS was very safe and non-irritating to 
penile and vaginal application.21,22 CS vaginal gel (6%) 
 was well tolerated as vaginal microbicide in both 
healthy and HIV-infected women, producing similar 
results to the commercial lubricant K-Y jelly.7,23−25 
Despite the promising preclinical results showing 
anti-HIV activity, CS failed to protect women in two 
large phase 3 clinical trials.18,26 Several hypotheses are 
still being investigated, but low antiviral potency and 
poor tissue penetration have been suggested as possible 
causes for the lack of correlation between clinical and 
preclinical results. 
The microbicides field has moved on to the 
development of more potent and specific compounds, 
selecting a few nucleoside and non-nucleoside reverse 
transcriptase inhibitors as its lead candidates (e.g., 
tenofovir, dapivirine, and UC781). As a result of such 
change, the current candidates display only antiviral 
activity and they are more susceptible to develop 
resistant viruses. 27 The selective activity of these drugs 
against HIV will leave women who have unprotected 
intercourse exposed to other sexually transmitted 
infections and pregnancy. Although CS is no longer 
being developed as an anti-HIV microbicide, it 
represents a good candidate to use as proof-of-concept 
for a substituted compound with dual, contraceptive and 
antimicrobial activity. Evaluation of novel CS 
derivatives or conjugates provides insights for designing 
the second generation of compounds with more optimal 
biological profile. 
Therefore, as proof-of-concept for a novel dual-
activity compound with potent anti-HIV activity, higher 
barrier to resistant virus and contraceptive activity, we 
herein report the synthesis and biological evaluation of 
bifunctional sodium cellulose sulfate conjugates with 
NRTIs, 3′-azido-2′,3′-dideoxythymidine (Zidovudine, 
AZT), 3′-fluoro-2′,3′-dideoxythymidine (Alovudine, 
FLT), and 2',3'-dideoxy-3'-thiacytidine (Lamivudine, 
3TC). Two different linkers (acetate and succinate) were 
used to conjugate the nucleoside analogs with CS in 
different loading values. Both nucleosides and CS 
contain alcohol functional groups and functionalization 
with linkers containing carboxylic acids allows 
conjugation through the formation of an ester moiety. 
Furthermore, it was expected that the ester conjugates 
would be cleaved by hydrolytic activity of cellular 
esterase enzymes, resulting in two separate components: 
CS (HIV entry blocker) and nucleoside analogs 
(NRTIs). Conjugates were also expected to exert 
contraceptive activity mediated by the released CS. 
The synthesis of cellulose sulfate acetate conjugates 
of AZT, FLT and 3TC was accomplished using building 
block synthetic strategy. For the synthesis of 
nucleoside-CSA conjugates, CS (1) was reacted first 
with 2-bromoacetic acid in presence of sodium 
hydroxide to render cellulose sulfate acetate (CSA, 2). 
CSA was then reacted with AZT, FLT, or N4-DMTr-
3TC to yield cellulose sulfate acetate conjugates of AZT 
(3, AZT-CSA, 1.78% loading), FLT (4, FLT-CSA, 
1.43% loading), or N4-DMTr-3TC-CSA (5′), 
respectively. Deprotection of DMTr group in 5′ 
afforded 3TC-CSA (5, 1.07% loading) (Scheme 1). 
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Scheme 1. Synthesis of cellulose sulfate acetate conjugates of AZT (3), 
FLT (4), and 3TC (5). 
 
For the synthesis of sodium cellulose sulfate 
conjugates linked to AZT or FLT through a succinate 
linker, AZT and FLT were first reacted with succinic 
anhydride to synthesize AZT succinate (6′) and FLT 
succinate (7′), which were then reacted with cellulose 
sulfate to afford cellulose sulfate succinate conjugates 
of AZT (6, 18.48% loading) and FLT (7, 7.87% 
loading) (Scheme 2). 
 
Scheme 2. Synthesis of AZT-succinate-CS (6) and FLT-succinate-CS (7) 
conjugates. 
The percentage of the loaded nucleosides on the 
 polymer through the acetate or succinate linkers was 
determined using the size exclusion chromatography 
(SEC) method based on the calibration curves of 
different concentrations of nucleosides versus area 
under the curve. The polymer-nucleoside conjugates 
were eluted at 9.15-9.50 min. It was assumed that the 
nucleosides were mainly conjugated through acetate or 
succinate linkers to the more reactive primary alcohols, 
but conjugation on secondary alcohols through linkers 
may also contribute to the percentage of loading. Both 
conjugations contribute to the overall anti-HIV activity 
after hydrolysis of the conjugate to the parent 
nucleosides. 
CS exhibited approximately 10-fold higher activity 
against X4 virus (IIIB strain, IC50 = 5.9 µg/ml)) than R5 
virus (BaL strain, IC50 = 62.5 µg/ml) (Table 1). These 
data were consistent with previously reported data on 
the weaker antiviral potency of anionic substances 
against macrophage-tropic R5 HIV-1.8,14,15 X4 strains 
possess higher number of positive charges on the V3 
loop of gp120 compared to those of R5 strains, making 
them more susceptible to inhibition by anionic 
polymers. 
In the present study, cellulose sulfate was 
conjugated with NRTIs, AZT, FLT, and 3TC, through 
different linkers to synthesize CS-nucleoside conjugates 
as bifunctional anti-HIV agents targeting different 
events in HIV life cycle. The conjugates were evaluated 
for their anti-HIV activity against lab-adapted, X4 and 
R5, cell-free HIV and wild-type and MDR clinical 
isolates and for contraceptive properties in an animal 
model. Cytotoxicity assays exhibited that none of the 
conjugates and the corresponding physical mixtures 
were cytotoxic at the highest concentration tested of 100 
µg/mL. 
Table 1 shows the antiviral activities of the 
cellulose sulfate-nucleoside conjugates with different 
loading percentages compared to those of CS, AZT, and 
FLT. Conjugation of CS with nucleosides improved CS 
antiviral activity against R5 strains. 
Nucleoside-CSA conjugates (AZT-CSA, 3, 1.78%; 
FLT-CSA, 4, 1.43%) demonstrated higher anti-HIV 
activity than that of CS (1). The improved anti-HIV 
activity of 3 (IC50 = 8.1 µg/mL) and 4 and 4 (IC50 = 1.5 
µg/mL) compared to CS (IC50 = 62.5 µg/ml) could be 
due to the release of two anti-HIV agents with different 
mechanisms of action and/or the presence of additional 
negatively charged acetate in the structure. Cellulose 
sulfate-acetate (2) was tested for anti-HIV activity as a 
control. Similar to 3 and 4, CSA (2) exhibited higher 
potency than CS (1), especially against the R5 strain, 
and surprisingly it was almost equally active to 3 and 4. 
The higher activity of 2 and its conjugates, 3 and 4, may 
be attributed to the presence of free negatively-charged 
carboxylate groups from the acetate groups substituted 
on CS, which enhance the overall negative charge 
density of the molecule. Although the substitution of 
acetate group on cellulose sulfate increased the anti-
HIV activity of CS, cellulose acetate (14) was 
completely inactive (Table 2), suggesting that the 
presence of sulfate is critical in maintaining the anti-
HIV activity of the polymer. 
Compared with AZT-CSA and FLT-CSA 
conjugates, 3TC-CSA (5, 1.07% loading) showed a 
significantly different anti-HIV profile. Conjugate 5 
revealed almost 37-fold less anti-HIV activity against 
X4 strain when compared with 3. The poor anti-HIV 
activity of 3TC conjugate could be due to the possible 
intermolecular interaction of free positively charged 4-
amino group of 3TC with the negatively-charged groups 
on CSA, which reduced the available free negative 
charge of the conjugate for binding to V3 loops of the 
virus. 
 
Table 1. Anti-HIV activity of nucleoside-cellulose sulfate conjugates. 
Compd Chemical Name 
(% loading) 
Cytotoxicity Antiviral 
Activity 
  
 IIIB BaL 
1 Sodium Cellulose Sulfate (Mol. wt. 2,000,900 Da) >100 5.9 62.5 
2 Cellulose Sulfate Acetate (CSA) >100 1.3 1.8 
3 
AZT-Cellulose Sulfate 
Acetate 
(AZT-CSA, 1.78%) 
>100 2.5 8.1 
4 
FLT-Cellulose Sulfate 
Acetate 
(FLT-CSA, 1.43%) 
>100 2.3 1.5 
5 
3TC-Cellulose Sulfate 
Acetate 
(3TC-CSA, 1.07%) 
>100 92.4 75.1 
6 
AZT-Succinate-Cellulose 
Sulfate 
(AZT-Suc-CS, 18.48%) 
>100 2.2 9.9 
7 
FLT-Succinate-Cellulose 
Sulfate 
(FLT-Suc-CS, 7.87%) 
>100 6.2 6.1 
AZT Zidovudine >100 2.4 4.2 
FLT Alovudine >100 <0.1 <0.1 
3TC Lamivudine >100 7.5 2.6 
Anti-HIV activity of compounds evaluated in single-round infection 
assays using HIV-1 IIIb (X4) and BaL (R5) and Galactosidase-transfected 
P4R5 cell line. Data are expressed as IC50 (antiviral) or CC50 (cytotoxicity) 
in µg/mL. 
 
To determine the contribution of sulfate group in 
generating anti-HIV activity of CS, cellulose phosphate 
and dextran acetate were studied as controls. These 
compounds were found to be totally inactive in viral 
inhibition assays (Table 2), suggesting that negatively-
charged acetate and phosphate alone are not sufficient 
for efficient interaction with HIV gp120 V3 loop. 
The anti-HIV activity of nucleoside-succinate-CS 
conjugates, AZT-succinate-CS (6, 18.48%) and FLT-
succinate-CS (7, 7.87%) was also evaluated. Both 
conjugates demonstrated at least 6-fold higher anti-HIV 
activity against R5 strains than CS, suggesting the 
contribution of the nucleoside analog in anti-HIV 
activity (Table 1). 
Although 6 and 7 had 10 and 6 times higher loading 
values than the corresponding conjugates substituted 
with acetate (3 and 4), respectively, the cellulose sulfate 
succinate conjugates were generally less active than 
 cellulose sulfate acetate conjugates (Table 1). The lower 
anti-HIV activity of conjugates containing succinate 
linker, despite of their higher nucleoside loading, 
compared to those containing acetate linker could be 
due to incomplete hydrolysis of 6 and 7 to parent 
nucleosides or the hydrolysis of the conjugate to 
generate inactive nucleoside-succinate derivatives 
instead of free nucleosides. Furthermore, upon 
hydrolysis of conjugates containing acetate linker, the 
acetate group will remain intact on the CS, contributing 
to the overall negative charge of the anionic polymer. 
The acetate is attached CS through methylene group and 
cannot be hydrolyzed like succinate ester conjugate. 
Further studies on the stability of the conjugates in vitro 
and in vivo will provide insights about the amount of the 
parent nucleosides and CS or CSA released and 
correlation with the anti-HIV activity. 
Table 2 shows the anti-HIV activity of the 
nucleoside-CS conjugates compared with the 
corresponding physical mixtures. The physical mixture 
of AZT (1.78%) + CSA (8) showed slightly better anti-
HIV activity against HIV than the corresponding AZT-
CSA conjugate (3). When CSA in 8 was replaced by CS 
in the physical mixture with AZT in 11 (18.48%), the 
anti-HIV activity was significantly reduced even with a 
higher loading of AZT in 11 because of the overall 
reduction of negative charge density in CS and the 
major contribution of CSA in overall activity. 
 
Table 2. Anti-HIV activities of cellulose acetate, dextran acetate, 
cellulose phosphate, and physical mixtures of nucleosides with CS, CSA, 
and cellulose. 
Compd  Chemical Name Cytotoxicity Antiviral Activity 
 (% loading)  IIIB BaL 
8 AZT (1.78 %) + CSA >100 1.7 2.5 
9 FLT (1.43 %) + CSA >100 0.7 0.3 
10 3TC (1.07%) + CSA >100 0.7 1.7 
11 AZT (18.48%) + CS >100 16.2 15.3 
12 FLT (1.43 %) + CS >100 6.2 7.1 
13 FLT (7.85 %) + CS >100 0.7 0.3 
14 Cellulose Acetate >100 >100 >100 
15 Dextran Acetate >100 >100 >100 
16 Cellulose Phosphate >100 72.1 >100 
17 AZT (1.78%) + Cellulose Acetate 
>100 75.5 8.5 
18 FLT (1.43%) + Cellulose Acetate 
>100 6.8 6.5 
19 3TC (1.07%) + Cellulose Acetate 
>100 73.9 22.4 
Anti-HIV activity of compounds evaluated in single-round infection 
assays using HIV-1 IIIb (X4) and BaL (R5) and Galactosidase-transfected 
P4R5 cell line. Data are expressed as IC50 (antiviral) or CC50 (cytotoxicity) 
in µg/mL. 
 
FLT-CSA conjugate (4) and 3TC-CSA (5) were 
compared with the corresponding physical mixtures, 9 
and 10, respectively. Similarly FLT-CSA conjugate (4) 
and 3TC-CSA (5) were less potent than their 
corresponding physical mixtures, 9 and 10. Physical 
mixture of CSA and FLT (9, 1.43%) exhibited 
approximately 3-5 fold higher anti-HIV activity against 
VBI (cell-free virus) when compared with the 
corresponding FLT-CSA conjugate (4, 1.43%). In the 
case of 10, the free amino group was not able to reduce 
the anionic interactions of sulfate group as described 
above in the conjugate 5. In general, the physical 
mixtures of 8, 9, and 10 exhibited better anti-HIV 
activity against HIV than the corresponding conjugates, 
3, 4, and 5, respectively, possibly because of the 
contribution of free negatively-charged acetate group of 
CSA in the physical mixtures. This is further confirmed 
by the fact physical mixtures containing CS (11, 12) 
were significantly less potent than those containing 
CSA (8, 9). 
Similarly, the overall anti-HIV activity of 9 was 
reduced by 8-22 times against when CSA in 9 (1.43%) 
was replaced with CS in 12 (1.43%), suggesting the 
importance of CSA in overall anti-HIV activity of these 
conjugates. 
Confirming the importance of the sulfate groups on 
the cellulose backbone, the physical mixture of AZT + 
cellulose acetate (17, 1.78%) showed significantly less 
antiviral activity than AZT-CSA conjugate (3, 1.78%) 
and AZT + CSA (8, 1.78%). Similarly, the physical 
mixture of FLT + cellulose acetate (18, 1.43%) showed 
9-21 fold less activity against cell-free virus when 
compared with FLT + CSA (9, 1.43%). These results 
were not surprising since cellulose acetate is an inactive 
polymer and the percentage of AZT or FLT were low in 
the physical mixture. 
In general, the physical and chemical combination 
of nucleosides with CS provided better antiviral activity 
against both X4 and R5 HIV-1 strains. The 
incorporation of acetate group on CS also improved 
anti-HIV activity, possibly by creating new negative 
charges after hydrolysis to free acetate groups on the 
polymer. The succinate spacer was less optimal than the 
acetate group for linking nucleosides and cellulose 
derivatives. 
AZT-CSA (3) and FLT-CSA (4) conjugates were 
further evaluated for their anti-HIV activity against 
wild-type (R5) and MDR clinical isolates and the data 
were compared with controls, CS and nucleosides 
(Table 3). CS (1) was active against MDR virus (IC50 = 
1.61 µg/mL), but showed less activity against R5 wild-
type (WT) HIV (IC50 > 20 µg/mL). Although FLT was 
equally potent against these WT and MDR viruses, as 
expected, AZT was less active against the MDR strain. 
 
 
 
 
 
 
 
 
Table 3. Anti-HIV activities of AZT-CSA and FLT-CSA conjugates 
against R5 and multidrug resistant HIV-1 clinical isolates. 
 Compd Chemical Name Type of Virus IC50  (µg/mL) 
R5 3.52 
3 AZT-CSA (1.78%) 
MDR 4.22 
R5 2.67 
4 FLT-CSA (1.43%) 
MDR 0.50 
R5 >20.0 
1 CS 
MDR 1.61 
AZT Zidovudine R5 MDR 
0.03 
0.3 
FLT Alovudine R5 MDR 
0.002 
0.004 
Assay endpoint = p24 level (ELISA); IC50 = The minimum drug 
concentration that inhibits HIV-induced cytopathic effect by 50%, 
calculated by using a regression analysis program for semilog curve 
fitting. HIV-1 clinical isolates: R5 = 92TH014; MDR = Multidrug 
resistant virus 7324-1. 
 
On the other hand, AZT-CSA (3) showed almost 
similar anti-HIV activity against R5 and MDR viruses. 
Furthermore, AZT-CSA (3) was more effective than CS 
against the R5 HIV-1 lab-adapted strain BaL. 
Conjugation of CSA and nucleosides improved both the 
R5 inhibitory activity of CS and the activity of AZT 
against MDR viruses. 
AZT-CSA conjugate (3) was selected for in vivo 
contraceptive efficacy testing in rabbits. Ex vivo mixing 
of CS and 3 prior to insemination of fertile female 
rabbits prevented pregnancy in 100% of the animals 
(Table 4). CS has been shown to display contraceptive 
properties and this result indicates that the contraceptive 
properties of CS are retained after AZT conjugation to 
the polymer. Thus, nucleoside-CS conjugates may have 
application as potential anti-HIV and contraceptive 
agents. 
 
Table 4. Contraceptive efficacy of AZT-CSA conjugate 3. 
Group 
Concentration 
(mg/ml) 
No. of 
Pregnant 
females/to
tal 
Pregnancy 
rate (%) 
Medium 
Control 
0 4/4 100 
1 1 0/5 0 
3 1 0/5 0 
Female rabbits were inseminated with pooled rabbit semen containing 1 
mg/mL of test compound or medium control. 
 
CS conjugates of AZT and FLT with acetate linker 
(AZT-CSA (3) and FLT-CSA (4)) and the physical 
mixture of AZT or FLT with CSA (8 and 9) exhibited 
higher anti-HIV activity than their corresponding 
conjugates with succinate linker (AZT-succinate-CS (6) 
and FLT-succinate-CS (7)), CS, and the physical 
mixtures of CS + AZT or FLT (11 and 12), possibly due 
to the creation of additional negative charges provided 
by the carboxylic acid of the acetate group.  
Unlike AZT and other nucleosides not tested in this 
study, the above-described conjugates were equally 
active against MDR virus and R5 WT HIV, suggesting 
a synergistic activity between entry and replication 
inhibitory mechanisms afforded by CS and nucleoside 
derivatives, respectively. A similar type of synergistic 
activity, albeit mechanistically different, was reported 
by Gantlett et al.28, when physically combining two 
other polyanions, PRO2000 and dextran sulfate, with 
other entry inhibitors such as the neutralizing antibody 
IgG1b12, the peptide-based fusion inhibitor T20, the 
CCR5 antagonist TAK779 and the cyanobacterial 
protein cyanovirin-N.  
These data demonstrate the feasibility of 
conjugating potent anti-HIV nucleosides with polymeric 
cellulose derivatives to produce compounds that display 
antimicrobial and contraceptive properties. In addition 
to enhanced antiviral activity against R5 and multidrug 
resistant viruses, the CSA-nucleoside combinations 
showed in vivo contraceptive activity, laying the 
foundation for the development of novel, dual-
protection products. 
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